Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering Sets Aside $150 Mil. For Liabilities In Marketing Investigations

Executive Summary

Schering-Plough is estimating its "minimum liability" in pending investigations of its marketing practices at the low end of recent settlements within the pharmaceutical industry
Advertisement

Related Content

Schering litigation reserves
Schering Moves Forward On GMP Work Plan; Is Marketing Settlement Next?
Schering-Plough Faces Criminal Case; Off-Label Promotion May Be One Count
GSK, Bayer Will Audit Sales Contracts Under “Best Price” Rebate Settlement
Medicaid Rebate Cases To Focus On “Slam Dunks”; Industry Wants Guidance
Schering PEG-Intron Supply Constraints Resolved; Earnings Forecast Cloudy
AstraZeneca Nexium Marketing Draws FTC Scrutiny; DoJ Looking At Prilosec 
AstraZeneca Nexium Marketing Draws FTC Scrutiny; DoJ Looking At Prilosec 
Schering Claritin, Rebetol Await FDA Certification After Consent Decree
TAP To Audit Marketing Documents Related To Top Lupron, Prevacid Buyers
Advertisement
UsernamePublicRestriction

Register

PS041369

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel